D. J. Chasman, D. Posada, L. Subrahmanyan, N. R. Cook, V. P. Stanton Jr. and P. M. Ridker, “Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction,” JAMA, Vol. 291, No. 23, 2004, pp. 2821-2827.
 C. L. Snozek, et al., “LDLR Promoter Variant and Exon 14 Mutation on the Same Chromosome Are Associated with an Unusually Severe FH Phenotype and Treatment Resistance,” European Journal of Human Genetics, Vol. 17, No. 1, 2009, pp. 85-89. doi:10.1038/ejhg.2008.199
 E. F. Christa, P. E. Mullis and A. V. Pandey, “Reduction in Hepatic Drug Metabolizing CYP3A4 Activities Caused by P450 Oxidoreductase Mutations Identified in Patients with Disordered Steroid Metabolism,” Biochemical and Biophysical Research Communications, Vol. 401, No. 1, 2010, pp. 149-153.
 C. Q. Lai, D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, et al., “Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants, The GOLDN Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 6, 2007, pp. 1417-1425.
 M. J. Garcia-Calvo, J. Lisnock, H. G. Bull, et al., “The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1),” Proceedings of the National Academy of Sciences, Vol. 102, No. 23, 2005, pp. 8132-8137.